Financial Report: Sanofi
2Q Revenues: €8.2 billion (-6%)
2Q Earnings: €762 million (-26%)
YTD Revenues: €16.1 billion (-7%)
YTD Earnings: €1.8 billion (-74%)
Comments: Pharmaceutical sales were up 2% to €6.3 billion driven by the Rare Blood Disorder and Immunology franchises, which was offset by declines in Diabetes and Established Rx Products. Sanofi Genzyme sales were up 14% driven by Dupixent and consolidation of Bioverativ. Vaccines sales were down 16% to €811 million related to the Pentaxim supply constraint in China. Consumer Healthcare sales increased 4% with growth in Europe and Emerging Markets. Diabetes and Cardiovascular sales were down 16% with the global Diabetes franchise down 12%. U.S. losses of exclusivity peak in the quarter. Lantus sales were down 21% to €891 million. Lovenox sales decreased 2% to €377 million. Aprovel/Avapro sales decreased 6% to €171 million, and Renvela/Renagel sales decreased 57% to €100 million, due to competition.